Exploring patient preferences regarding the use of combination therapy with endothelin receptor antagonist (ERA) + phosphodiesterase-5 inhibitors (PDE5i)
STCT offers potential benefits in reducing pill burden, improving convenience, and possibly facilitating treatment initiation and adherence. However, cost remains a significant factor influencing patient decision-making in PAH therapy in the United States. Addressing cost concerns may increase the acceptance of ERA + PDE5i therapies and STCT among patients with PAH.
Authors
- Martha Kingman (ORCID: https://orcid.org/0000-0002-3560-2066)
- Ashley Martin (ORCID: https://orcid.org/0009-0005-8170-1638)
- Melisa Wilson (ORCID: https://orcid.org/0000-0003-3359-0871)
- Lana Melendres‐Groves (ORCID: https://orcid.org/0009-0001-7964-8322)
- Nicholas A. Kolaitis (ORCID: https://orcid.org/0000-0002-4586-959X)
- Sana Mirza (ORCID: https://orcid.org/0000-0002-4103-4712)
- Hafizur Rahman (ORCID: https://orcid.org/0000-0002-2742-049X)
- Carly J. Paoli (ORCID: https://orcid.org/0000-0002-1331-9462)
- November McGarvey (ORCID: https://orcid.org/0000-0003-4439-4788)
- Gabriela Gomez Rendon (ORCID: https://orcid.org/0009-0007-1303-5201)
- Abraham Lee
- David Arturo Juarez Lopez (ORCID: https://orcid.org/0009-0002-2310-3793)
Institutions
- Johnson & Johnson (United States) (US)
- University of New Mexico (US)
- University of California, San Francisco (US)
- AdventHealth Orlando (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- JHLT Open
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1016/j.jhlto.2025.100410
- Primary Topic
- Blood Pressure and Hypertension Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00